Ferran Fece de la Cruz (@FerranFeceCruz) header
Ferran Fece de la Cruz (@FerranFeceCruz) profile picture

Ferran Fece de la Cruz

@FerranFeceCruz

Group Leader & Associate Professor | BRIC–@UCPH_Research & Finsen Lab–@Rigshospitalet | Tumor evolution & drug resistance | Former MGH/@harvardmed | Catalan

 Copenhagen (Denmark)
linkedin.com/in/Ferran-PhD
Joined April 2015
  • Tweets1.5K
  • Following2.2K
  • Followers619
88Media
Photo by Ferran Fece de la Cruz (@FerranFeceCruz)Photo by Ferran Fece de la Cruz (@FerranFeceCruz)Photo by Ferran Fece de la Cruz (@FerranFeceCruz)Photo by Ferran Fece de la Cruz (@FerranFeceCruz)Photo by Ferran Fece de la Cruz (@FerranFeceCruz)Photo by Ferran Fece de la Cruz (@FerranFeceCruz)Photo by Ferran Fece de la Cruz (@FerranFeceCruz)Photo by Ferran Fece de la Cruz (@FerranFeceCruz)Photo by Ferran Fece de la Cruz (@FerranFeceCruz)Photo by Ferran Fece de la Cruz (@FerranFeceCruz)
Happy to report the first clinical evidence revealing how tumors develop resistance to p53-Y220C reactivators out today @CD_AACR @MassGenBrigham @harvardmed #CorcoranLab #Rezatapopt #p53Y220C #PYNNACLE aacrjournals.org/cancerdisco…
Acquired On-Target Alterations Drive Clinical Resistance to p53-Y220C Reactivators

Acquired On-Target Alterations Drive Clinical Resistance to p53-Y220C Reactivators

On-target TP53 secondary mutations arise during progression on the p53-Y220C reactivator rezatapopt, either abolishing p53 function or reshaping the Y220C pocket to block drug binding, defining...

aacrjournals.org
2
5
2
14
3,741
Ferran Fece de la Cruz retweeted
Laura Soucek (@LauraSoucek) profile picture
Laura Soucek@LauraSoucekNov 2
Fa 15 anys vaig arribar a Barcelona per perseguir un somni: convertir l'impossible en una nova oportunitat per als pacients amb càncer. Gràcies a @diariARA i @saez_cristina per explicar la nostra història i celebrar la força de la recerca catalana! ❤️ ara.cat/ciencia-medi-ambient…
"Em quedaven tres mesos de vida": la ciència que ha transformat la salut a Catalunya

"Em quedaven tres mesos de vida": la ciència que ha transformat la salut a Catalunya

En 20 anys el país ha esdevingut una de les bioregions europees de referència en recerca biomèdica, innovació i assajos clínics

ara.cat
7
30
833
Ferran Fece de la Cruz retweeted
Sasha Gusev (@SashaGusevPosts) profile picture
Sasha Gusev
@SashaGusevPostsOct 29
You can have a fun lab without sleeping with the fellows in the program you direct!
Image from Sasha Gusev (@SashaGusevPosts)
Neeraja Deshpande (@neerajadeshp) profile pictureNeeraja Deshpande
@neerajadeshpOct 28
One of the things that got me about the @DMSabatini story was the allegation that his lab promoted “bro culture.” Not only is being a bro not a crime (no matter what some might have you think) but labs, especially ones that operate at such a high level, rely on people being motivated, being inspired, and yes, having fun. I loved Sabatini’s response to my question in my interview with him for @PirateWires, on how American science has become corporate and sterile:
Image from Neeraja Deshpande (@neerajadeshp)
28
21
3
469
32,051
European Research Council (ERC) (@ERC_Research) profile pictureEuropean Research Council (ERC)
@ERC_ResearchOct 27
A record 7,710 proposals – a 60.4% increase to 2026 – for #ERCStG 2027! Physical Sciences & Engineering are in the lead (43%), followed by Social Sciences & Humanities (29%), and Life Sciences (28%). erc.europa.eu/news-events/ne…
129
Ferran Fece de la Cruz retweeted
Adam C Palmer (@ac_palmer) profile picture
Adam C Palmer@ac_palmerOct 26
Anyone interested in cancer medicine needs to see the current front page of @NEJM nejm.org It's one historic advance after another after another on there right now
Image from Adam C Palmer (@ac_palmer)
Image from Adam C Palmer (@ac_palmer)
Image from Adam C Palmer (@ac_palmer)
Image from Adam C Palmer (@ac_palmer)
22
178
19
835
56,118
Diva! #KRAS #KRASCENDO1 @myESMO #ESMO26
Image from Ferran Fece de la Cruz (@FerranFeceCruz)
1
1
148
Ferran Fece de la Cruz retweeted
Julien Mazieres (@JulienMazieres) profile picture
Julien Mazieres@JulienMazieresOct 23
When shareholders are informed before the medical community… this is not respectful to investigators and patients involved in clinical trials.
ESMO - Eur. Oncology (@myESMO) profile pictureESMO - Eur. Oncology
@myESMOOct 22
#ESMO26: The embargo on LBA1, “INTerpath-001: Phase 3 study of the mRNA-based individualised neoantigen therapy intismeran autogene plus pembrolizumab versus pembrolizumab alone for adjuvant treatment of resected stage IIB-IV melanoma”, has been breached. As the data are now publicly available, ESMO has released the information contained in the abstract and has lifted the embargo on the full dataset.
2
6
672
🤯 science.org/doi/10.1126/scie…
Germline EGFR T790M mutation and lung cancer risk

Germline EGFR T790M mutation and lung cancer risk

Most lung cancers are tobacco related, with genetic factors influencing smoking behavior identified through genome-wide association studies. However, inherited risk in familial and non-smoking-rela...

science.org
89
Topoisomerase inhibitor vs. a B7-H3-targeting ADC linked to a topoisomerase inhibitor payload 🤯 Good news for the #SCLC community! @SclcSMASHERS @NEJM #Phase3 nejm.org/doi/full/10.1056/NE…
Image from Ferran Fece de la Cruz (@FerranFeceCruz)
1
1
130
“Women living with #mBC face an uphill battle as their tumors evolve to escape treatment. This marks the first FDA approval guided by the detection of a resistance mutation in ctDNA before imaging tests show that the disease is progressing." #SERENA6 #ESR1 fda.gov/news-events/press-an…
FDA Grants Accelerated Approval to a New Breast Cancer Treatment

FDA Grants Accelerated Approval to a New Breast Cancer Treatment

The U.S. Food and Drug Administration today expanded treatment options for adult patients with advanced breast cancer, reflecting the FDA’s commitment to advancing medical innovation and getting new...

fda.gov
1
130
Ferran Fece de la Cruz retweeted
Recerca i Universitats (@recercauniscat) profile picture
Recerca i Universitats
@recercauniscatSep 3
Reconeixement a l'excel·lència de la recerca 📢 5 investigadors del sistema català de coneixement reben ajuts Starting Grant de l’@ERC_Research Són els més prestigiosos i competitius del món i impulsen l'inici de la carrera científica Mésℹ️ 🔗 erc.europa.eu/news-events/ne… #ERCStG
5 investigadors del sistema català de coneixement reben ajuts Starting Grant de l’@ERC_Research 2026

ALT 5 investigadors del sistema català de coneixement reben ajuts Starting Grant de l’@ERC_Research 2026

22
1
58
3,294
PYNNACLE Phase 2 update! #Y220C #Rezatapopt targetedonc.com/view/rezatap…
Rezatapopt Shows 46% ORR in TP53 Y220C–Mutated Ovarian Cancer | Targeted Onc - Immunotherapy,...

Rezatapopt Shows 46% ORR in TP53 Y220C–Mutated Ovarian Cancer | Targeted Onc - Immunotherapy,...

Rezatapopt hit a 46% ORR in TP53 Y220C–mutated ovarian cancer in the PYNNACLE trial, with an FDA filing expected in Q1 2027.

targetedonc.com
118
Ferran Fece de la Cruz retweeted
Jordi Ribas (@JordiRib1) profile picture
Jordi Ribas
@JordiRib1Sep 2
Estic molt il·lusionat d’anunciar que la “Ribas Family Early Career Professorship in Catalan and Romance Languages and Cultures” de la Universitat de Michigan ha obert el període de presentació de candidatures per a una plaça de professor titular. Aquesta càtedra permanent és una contribució de la meva família a la Universitat i al Govern i poble de Catalunya, en part per agraïment per les beques que em van concedir durant els meus estudis de doctorat en enginyeria. I’m excited to announce that the “Ribas Family Early Career Professorship in Catalan and Romance Languages and Cultures” at the University of Michigan is now inviting applications for a tenure-track position. This Professorship is my family’s endowment and contribution to both the University and the Government and people of Catalonia who supported me financially through my PhD studies in Engineering. Please find more details on the position here: msft.it/6015appbt
Image from Jordi Ribas (@JordiRib1)
54
549
15
1,458
81,333
Ferran Fece de la Cruz retweeted
Elizabeth McKenna (@ElizSMcKenna) profile picture
Elizabeth McKenna@ElizSMcKennaSep 2
Congrats!! Love to see when first authors in @CD_AACR move on to start their own labs!
Image from Elizabeth McKenna (@ElizSMcKenna)
Image from Elizabeth McKenna (@ElizSMcKenna)
Ferran Fece de la Cruz (@FerranFeceCruz) profile pictureFerran Fece de la Cruz@FerranFeceCruzSep 2
Replying to @ElizSMcKenna
🙋🏻‍♂️
Image from Ferran Fece de la Cruz (@FerranFeceCruz)
3
1
30
5,387
Ferran Fece de la Cruz retweeted
IDIBAPS (@idibaps) profile picture
IDIBAPS@idibapsAug 27
🌍🔬 Catalunya és terra de recerca, innovació i oportunitats Amb el programa impulsat per #IDIBAPS, @ISGLOBALorg i @HMar_research, promovem la llengua i la cultura catalanes per afavorir la integració del talent internacional Benvinguts a Catalunya!👋
3
9
768
Ferran Fece de la Cruz retweeted
nature (@Nature) profile picture
nature
@NatureAug 26
The US FDA have now approved this drug for use against a cancer previously thought to be "undruggable" go.nature.com/4qHLuOr
Landmark cancer trial shows success against ‘undruggable’ cancer — raising hopes for future...

Landmark cancer trial shows success against ‘undruggable’ cancer — raising hopes for future...

Nature - Unprecedented results against a stubbornly hard-to-treat cancer are boosting optimism that other challenging tumours will be next.

nature.com
5
95
6
384
59,172
Daraxonrasib is approved!!!! #RAS #pancsm @KRASKickers fda.gov/news-events/press-an…
FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic Cancer

FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic Cancer

The U.S. Food and Drug Administration today approved Rasonque (daraxonrasib), a RAS inhibitor for the most common form of pancreatic cancer—delivering a new treatment option to patients with advanced...

fda.gov
4
220
Melanoma to rhabdomyosarcoma transformation after ICB and HDAC-i. Let's talk about tumor evolution under treatment pressure 🤯 @MedCellPress cell.com/med/abstract/S2666-…
Image from Ferran Fece de la Cruz (@FerranFeceCruz)
2
204
🤯🤯🤯 nature.com/articles/s41586-0…
Human brain organoids record the passage of time over multiple years

Human brain organoids record the passage of time over multiple years

Nature - Human brain organoids were developed for over five years in culture to demonstrate that brain cells can continue to mature and record the passage of time, following human-specific...

nature.com
1
146
Ferran Fece de la Cruz retweeted
Nature Medicine (@NatureMedicine) profile picture
Nature Medicine
@NatureMedicineAug 18
A new study reveals mechanisms of resistance to daraxonrasib, highlighting putative combination approaches. Read the News & Views from Grainne O'Kane & colleagues: dlvr.it/TV46sH

From RAS inhibitor resistance to rational combination strategies

Nature Medicine - As new drugs that target mutant RAS redefine the therapeutic landscape in the treatment of pancreatic cancer, understanding and intercepting resistance is critical; a new study...

nature.com
15
1
55
12,527
Ferran Fece de la Cruz retweeted
William L Hwang (@DrWilliamHwang) profile picture
William L Hwang@DrWilliamHwangAug 18
Please join us at the inaugural MGB Cancer Institute Pancreatic Cancer Symposium @MGBResearchNews, details linked tinyurl.com/2xba57j3
Mass General Brigham Pancreatic Cancer Symposium | Harshabad Singh posted on the topic | LinkedIn

Mass General Brigham Pancreatic Cancer Symposium | Harshabad Singh posted on the topic | LinkedIn

To mark this historic time in the treatment of pancreatic cancer it is a pleasure to announce the Inaugural Mass General Brigham Cancer Institute Pancreatic Cancer Symposium, which we will host on...

linkedin.com
2
2
23
1,821
Load more